V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017358 | 160013643 | 0 | 109 | Curative (C) | 2017-07-10 | 2017-07-20 | null | null | null | NOT MATCHED | 100480278 |
| 160017360 | 160013644 | 1.61 | 11.3 | null | null | 2016-09-08 | Etoposide + Ifosfamide (5 days) | 02 | null | EW EUROEWING 2012 ARM A/B BUMEL | 100725871 |
| 160017362 | 160013645 | 1.61 | 63.7 | null | null | 2018-11-26 | null | 01 | null | CISPLATIN + ETOPOSIDE | 101168777 |
| 160017368 | 160013646 | 1.65 | 91.7 | Palliative (P) | 2019-12-16 | 2019-12-17 | Olaratumab | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100250842 |
| 160017369 | 160013647 | 1.67 | 141.6 | Curative (C) | 2017-04-20 | 2017-04-27 | Cyclophosphamide oral | 02 | N | RUCAPARIB | 101146230 |
| 160017370 | 160013648 | 1.93 | 31 | null | null | 2018-04-05 | GEMCITABINE | 02 | null | ETOPOSIDE + IFOSFAMIDE | 100721352 |
| 160017374 | 160013649 | 0 | 15.1 | Curative (C) | 2019-09-13 | 2019-09-29 | Cyclophosphamide + Vincristine | 02 | N | IRINOTECAN + TEMOZOLOMIDE | 100421031 |
| 160017375 | 160013650 | 1.67 | 68.9 | Curative (C) | 2019-08-21 | 2019-09-13 | Cyclophosphamide oral | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101613656 |
| 160017376 | 160013651 | 1.58 | 0 | Palliative (P) | 2020-01-15 | 2020-04-12 | DABRAFENIB + TRAMETINIB | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100140092 |
| 160017378 | 160013652 | 1.57 | 20.9 | Curative (C) | 2016-06-26 | 2016-07-05 | MELPHALAN | 02 | null | NOT MATCHED | 100810764 |
| 160017381 | 160013653 | 1.68 | 0 | Palliative (P) | 2018-07-11 | 2018-08-23 | VINCRISTINE | 99 | N | ANTIBODY NBL | 100927627 |
| 160017382 | 160013654 | 1.74 | 63.9 | null | 2016-10-02 | 2016-10-23 | STS Rhabdomyosarcoma RMS 2005 IVADo | null | null | ETOPOSIDE | 100578458 |
| 160017385 | 160013655 | 1.83 | 73 | Adjuvant (A) | 2018-04-30 | 2018-04-30 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | null | CYCLOPHOSPHAMIDE HIGH DOSE | 100674697 |
| 160017388 | 160013656 | 0 | 9.6 | null | 2020-02-02 | 2020-02-02 | CYCLOPHOSPHAMIDE + VINORELBINE | null | null | STS NON-RHABDO EPSSG 2005 IFOS | 101109548 |
| 160017390 | 160013657 | 0 | 78 | null | 2019-11-03 | 2019-11-03 | EW EuroEwing 2012 Arm A/B Zol Acid | 02 | null | NB HRNBL-1 COJEC IND COURSE B | 100851729 |
| 160017395 | 160013658 | 1.73 | 80.5 | null | 2017-08-14 | 2017-09-12 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | null | CONFIRM TRIAL | 101824416 |
| 160017396 | 160013659 | 1.62 | 64 | null | 2018-05-10 | 2018-05-10 | Niraparib | 02 | null | NIRAPARIB | 101280426 |
| 160017398 | 160013660 | null | 96.4 | Curative (C) | 2020-10-31 | 2020-11-21 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100262428 |
| 160017400 | 160013661 | 0 | 70.2 | null | 2019-02-24 | 2019-04-07 | PEMBROLIZUMAB | 02 | null | CAPECITABINE | 100249403 |
| 160017401 | 160013662 | 1.82 | 67.5 | null | 2022-03-19 | 2022-03-19 | Trial Unspecified | 02 | null | EW EUROEWING 2012 ARM B VC | 100131402 |
| 160017404 | 160013663 | 1.63 | 86.8 | Neo-adjuvant (N) | 2017-03-12 | 2017-03-15 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | EW EUROEWING 2012 ARM B VC | 100331605 |
| 160017406 | 160013664 | 1.66 | 84.7 | null | 2019-08-30 | 2019-09-06 | Pemetrexed | 01 | null | CONFIRM TRIAL | 101715816 |
| 160017407 | 160013665 | 0 | 95 | null | 2017-04-17 | 2017-04-21 | Ribociclib | 02 | null | CEDIRANIB | 100811708 |
| 160017408 | 160013666 | 1.73 | 77 | null | 2017-08-15 | 2017-08-15 | Olaparib | 02 | null | DINUTUXIMAB BETA | 100720759 |
| 160017416 | 160013667 | 0 | 84.9 | Palliative (P) | 2017-11-27 | 2017-11-28 | EW EuroEwing 2012 Arm B VDC/IE | 02 | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101132440 |
| 160017418 | 160013668 | null | 72.1 | Palliative (P) | 2020-09-25 | 2020-09-26 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100627889 |
| 160017419 | 160013669 | 0 | 94 | Palliative (P) | 2016-05-20 | 2016-05-25 | Olaparib | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100343892 |
| 160017429 | 160013672 | null | null | Curative (C) | 2016-02-17 | 2017-02-05 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | EW EUROEWING 2012 ARM B IE | 101753260 |
| 160017434 | 160013673 | 1.27 | 79.6 | null | 2020-07-11 | 2020-07-11 | Ifosfamide | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 100288250 |
| 160017435 | 160013674 | 1.78 | 18 | Palliative (P) | 2017-04-25 | 2019-04-17 | Etoposide + Ifosfamide (3 days) | 02 | null | CISPLATIN + DOXORUBICIN | 100270980 |
| 160017444 | 160013675 | 1.72 | 104 | null | 2018-07-13 | 2018-07-26 | EW EuroEwing 2012 Arm B IE | 02 | null | TRIAL | 100126331 |
| 160017452 | 160013676 | 1.66 | 92.9 | Palliative (P) | 2017-07-28 | 2017-07-30 | null | Y | N | TRIAL | 101226834 |
| 160017454 | 160013677 | 1.68 | 67.6 | null | 2015-02-26 | 2015-02-26 | CARBOPLATIN + LIPOSOMAL DOX | N | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100695137 |
| 160017457 | 160013678 | 0 | 9.9 | null | 2018-12-27 | 2018-12-28 | null | null | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100866679 |
| 160017458 | 160013679 | 1.78 | 48.1 | Curative (C) | 2018-06-29 | 2018-07-16 | STS Rhabdo VIT0910 Vinc Irino Temoz | N | N | IFOSFAMIDE | 100059797 |
| 160017462 | 160013680 | 1.65 | 14.3 | Palliative (P) | 2019-12-01 | 2019-12-28 | Abiraterone | 02 | N | IRINOTECAN + CISPLATIN + MITOMYCIN | 100297998 |
| 160017464 | 160013681 | 1.57 | 92.1 | Curative (C) | 2018-03-16 | 2018-03-25 | Trial Unspecified | 02 | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 101623145 |
| 160017466 | 160013682 | 1.61 | 67.6 | Curative (C) | 2017-07-14 | 2017-07-21 | VAI (Ifos 3g/m2) | 02 | N | ETOPOSIDE | 101683920 |
| 160017471 | 160013684 | 1.64 | 25.8 | null | 2017-09-06 | 2017-09-10 | EW EuroEwing 2012 Arm B VC | 02 | null | NB HRNBL-1 BUMEL MAT | 101392484 |
| 160017473 | 160013685 | 1.93 | 100.3 | Curative (C) | 2018-12-11 | 2018-12-13 | PEMBROLIZUMAB | 02 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101144339 |
| 160017476 | 160013686 | 1.62 | 114.6 | Curative (C) | 2018-01-06 | 2018-01-06 | NB HRNBL | Y | N | BRIGATINIB | 101680592 |
| 160017480 | 160013687 | 1.77 | 67.7 | null | null | null | LORLATINIB | 02 | null | EW EUROEWING 99 : VACTI | 100968982 |
| 160017488 | 160013688 | 1.56 | 109 | null | 2017-08-31 | 2017-09-19 | NB HRNBL-1 COJEC Ind COURSE A | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 101263396 |
| 160017489 | 160013689 | 1.77 | 51 | Palliative (P) | 2019-06-22 | 2019-06-23 | null | N | N | VINCRISTINE | 101800761 |
| 160017490 | 160013690 | 1.6 | 13 | null | 2018-07-28 | 2019-01-21 | Trial Unspecified | 2 | null | CAPECITABINE + TEMOZOLOMIDE | 100770715 |
| 160017493 | 160013691 | 0 | 94.25 | Palliative (P) | 2015-03-16 | 2015-03-26 | R CODOX-M/ R IVAC | 02 | N | LENALIDOMIDE | 101576975 |
| 160017494 | 160013692 | 1.82 | 57 | Palliative (P) | 2017-06-04 | 2017-06-11 | EW EuroEwing 2012 Arm B VDC/IE | 02 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101624149 |
| 160017497 | 160013694 | 0 | 87.2 | null | 2016-11-25 | 2017-01-20 | Etoposide oral | null | null | PEMBROLIZUMAB | 101846682 |
| 160017499 | 160013695 | 1.85 | 2.3 | null | 2018-07-20 | 2018-08-01 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | CISPLATIN + DOXORUBICIN | 100444990 |
| 160017502 | 160013696 | 1.78 | 77.4 | Curative (C) | 2019-08-06 | 2019-09-26 | Niraparib | 02 | N | OLARATUMAB | 101525945 |